Publicacións en colaboración con investigadores/as de Mayo Clinic (7)

2024

  1. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

    The Lancet, Vol. 404, Núm. 10459, pp. 1227-1239

  2. Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor

    Clinical Genitourinary Cancer, Vol. 22, Núm. 6

2023

  1. Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study

    European Urology, Vol. 84, Núm. 3, pp. 321-330

  2. Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors

    Journal of the National Cancer Institute, Vol. 115, Núm. 12, pp. 1605-1615

2021

  1. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study

    Journal of Clinical Oncology, Vol. 39, Núm. 33, pp. 3725-3736

2013

  1. Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: A subgroup analysis of the phase III RADIANT-2 study

    Oncologist, Vol. 18, Núm. 1, pp. 46-53

2011

  1. Therapy innovations: Tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors

    Cancer and Metastasis Reviews, Vol. 30, Núm. SUPPL. 1